摘要
目的探讨坦度螺酮联合左乙拉西坦片对癫痫患者S-100β蛋白(S-100β)、超敏C-反应蛋白(hs-CRP)、丙二醛(MDA)水平的影响。方法将2018年4月至2020年4月我院收治的118例癫痫患者随机分为单药组和联合组。单药组口服左乙拉西坦片进行治疗,联合组在单药组基础上口服坦度螺酮胶囊进行治疗。比较两组患者的临床疗效、不良反应发生情况、心理状况和S-100β、 hs-CRP、 MDA水平。结果联合组的总有效率为96.61%,高于单药组的77.97%(P <0.05)。治疗后,联合组的HAMA-14、 HAMD-17评分低于单药组(P <0.05)。治疗后,联合组的S-100β、 hs-CRP、 MDA水平低于单药组(P <0.05)。单药组的不良反应发生率为3.39%,与联合组的5.08%比较无统计学差异(P>0.05)。结论坦度螺酮联合左乙拉西坦片治疗癫痫患者效果较佳,可明显改善患者的心理状况,降低S-100β、 hs-CRP、 MDA水平,且安全性较高。
Objective To explore the influence of tandospirone combined with levetiracetam tablets on the S-100βprotein(S-100β),high sensitivity C-reactive protein(hs-CRP)and malondialdehyde(MDA)levels in patients with epilepsy.Methods 118 patients with epilepsy admitted to our hospital from April 2018 to April 2020 were randomly divided into single drug group and combined group.The single drug group was treated with levetiracetam tablets,and the combined group was treated with tandospirone capsules on the basis of the single drug group.The clinical efficacy,adverse reactions,psychological status and the S-100β,hs-CRP and MDA levels were compared between the two groups.Results The total effective rate of the combined group was 96.61%,higher than 77.97%of the single drug group(P<0.05).After treatment,the HAMA-14 and HAMD-17 scores of the combined group were lower than those of the single drug group(P<0.05).After treatment,the S-100β,hs-CRP and MDA levels of the combined group were lower than those of the single drug group(P<0.05).The incidence of adverse reactions in the single drug group was 3.39%,which had no statistical difference with 5.08%in the combined group(P>0.05).Conclusions Tandospirone combined with levetiracetam tablets in the treatment of epilepsy patients has better effect,which can significantly improve the psychological status,and reduce the S-100β,hs-CRP and MDA levels,with higher safety.
作者
孙晓静
肖悠美
张存玲
袁学谦
SUN Xiaojing;XIAO Youmei;ZHANG Cunling;YUAN Xueqian(Zhengzhou People's Hospital,Zhengzhou 450053,China)
出处
《临床医学工程》
2021年第3期341-342,共2页
Clinical Medicine & Engineering
